MX367255B - Aminoesteroides para tratamiento de una enfermedad asociada con proteina fosfatasa 1b (ptp1b). - Google Patents

Aminoesteroides para tratamiento de una enfermedad asociada con proteina fosfatasa 1b (ptp1b).

Info

Publication number
MX367255B
MX367255B MX2014012619A MX2014012619A MX367255B MX 367255 B MX367255 B MX 367255B MX 2014012619 A MX2014012619 A MX 2014012619A MX 2014012619 A MX2014012619 A MX 2014012619A MX 367255 B MX367255 B MX 367255B
Authority
MX
Mexico
Prior art keywords
treatment
aminosteroids
associated disease
ptp1b
ptp1b associated
Prior art date
Application number
MX2014012619A
Other languages
English (en)
Other versions
MX2014012619A (es
Inventor
Mclane Michael
Ruiz-White Inez
Lee Maloy W
R Wolfe Henry
Original Assignee
Ohr Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohr Pharmaceutical Inc filed Critical Ohr Pharmaceutical Inc
Publication of MX2014012619A publication Critical patent/MX2014012619A/es
Publication of MX367255B publication Critical patent/MX367255B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Esta solicitud se relaciona con el uso de compuestos aminoesteroides para la inhibición selectiva de la enzima PTP1B en un mamífero para el tratamiento de diabetes.
MX2014012619A 2012-04-20 2013-04-19 Aminoesteroides para tratamiento de una enfermedad asociada con proteina fosfatasa 1b (ptp1b). MX367255B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261636252P 2012-04-20 2012-04-20
PCT/US2013/037330 WO2013158970A2 (en) 2012-04-20 2013-04-19 Aminosteroids for the treatment of a ptp1b associated disease

Publications (2)

Publication Number Publication Date
MX2014012619A MX2014012619A (es) 2015-01-15
MX367255B true MX367255B (es) 2019-08-12

Family

ID=48325893

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014012619A MX367255B (es) 2012-04-20 2013-04-19 Aminoesteroides para tratamiento de una enfermedad asociada con proteina fosfatasa 1b (ptp1b).
MX2019009539A MX2019009539A (es) 2012-04-20 2014-10-17 Aminoesteroides para tratamiento de una enfermedad asociada con proteina fosfatasa 1b ( ptp1b).

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019009539A MX2019009539A (es) 2012-04-20 2014-10-17 Aminoesteroides para tratamiento de una enfermedad asociada con proteina fosfatasa 1b ( ptp1b).

Country Status (15)

Country Link
US (6) US9546194B2 (es)
EP (2) EP3556765B1 (es)
JP (4) JP6165843B2 (es)
KR (3) KR20150003798A (es)
AU (3) AU2013249111B2 (es)
CA (1) CA2870671C (es)
DK (1) DK2838907T3 (es)
ES (1) ES2736310T3 (es)
HR (1) HRP20191348T1 (es)
HU (1) HUE044769T2 (es)
MX (2) MX367255B (es)
PL (1) PL2838907T3 (es)
PT (1) PT2838907T (es)
TR (1) TR201911039T4 (es)
WO (1) WO2013158970A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150003798A (ko) * 2012-04-20 2015-01-09 오에이치알 파마서티컬, 인코포레이티드 Ptp1b 연관 질병의 치료용 아미노스테로이드
US10040817B2 (en) * 2013-10-03 2018-08-07 Enterin Laboratories, Inc. Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same
GB201700567D0 (en) 2017-01-12 2017-03-01 Genagon Therapeutics Ab Therapeutic agents
EP3678671A4 (en) * 2017-09-08 2022-12-07 Enterin, Inc. METHODS OF TREATMENT OF SLEEPING DISEASES, SLEEP DISORDERS AND RELATED SYMPTOMS USING AMINOSTEROL COMPOSITIONS
CN107802626B (zh) * 2017-10-11 2020-01-21 南昌大学 降血糖组合物及其制备方法、用途
CA3081815A1 (en) * 2017-11-06 2019-05-09 Cold Spring Harbor Laboratory Method and compositions for forming a copper-containing complex and uses thereof
KR20200146038A (ko) * 2018-03-27 2020-12-31 엔테린, 인코포레이티드 환각 및 이와 관련된 상태를 치료하는 방법 및 조성물
US12215128B2 (en) 2018-07-20 2025-02-04 Cold Spring Harbor Laboratory (Pyridinylmethyl)butanediamine derivatives that chelate copper
MX2022001449A (es) 2019-08-02 2022-04-06 Enterin Inc Compuestos de aminoesterol humano ent-03, composiciones relacionadas que comprenden los mismos y metodos para usar los mismos.
CA3149480A1 (en) * 2019-08-02 2021-02-11 Enterin, Inc. Human squalamine derivatives, related compositions comprising the same, and methods of using the same
WO2023230593A1 (en) 2022-05-27 2023-11-30 Cold Spring Harbor Laboratory Ptp1b inhibitors for treating lung injury

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2403683A (en) * 1942-04-25 1946-07-09 Relchstein Tadeus Compounds of the cyclopentanopolyhydrophenanthrene series and process of making same
US3636210A (en) * 1968-02-02 1972-01-18 Merck & Co Inc Cholanic acid and cholenic acid compositions and method of treatment
IT1255450B (it) * 1992-06-30 1995-10-31 Montefarmaco Spa Uso di acidi biliari come agenti antivirali
AU6392894A (en) * 1993-02-26 1994-09-14 Magainin Pharmaceuticals, Inc. Chemical synthesis of squalamine
CA2157594A1 (en) * 1993-03-10 1994-09-15 Leah L. Frye Steroid derivatives, pharmaceutical compositions containing them, and their use as antibiotics or disinfectants
US5856535A (en) 1994-08-18 1999-01-05 Magainin Pharmaceuticals, Inc. Aminosterol ester compounds
US5792635A (en) * 1995-06-07 1998-08-11 Magainin Pharmaceuticals, Inc. Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
AU723663C (en) 1995-06-07 2001-11-01 Magainin Pharmaceuticals, Inc. Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE), pharmaceutical methods and compositions employing such inhibitors, and processes for evaluating the NHE-inhibitory efficacy of compounds
US7410959B1 (en) * 2000-07-13 2008-08-12 Genaera Corporation Therapeutic uses for aminosterol compounds
WO2001017516A2 (en) 1999-09-10 2001-03-15 Novo Nordisk A/S Method of inhibiting protein tyrosine phosphatase 1b and/or t-cell protein tyrosine phosphatase and/or other ptpases with an asp residue at position 48
EP1214324B1 (en) 1999-09-10 2006-06-14 Novo Nordisk A/S MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases)
EP1214325B1 (en) 1999-09-10 2005-11-09 Novo Nordisk A/S MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases)
JP2004506599A (ja) * 1999-12-09 2004-03-04 ジェネーラ・コーポレーション 喘息および関連疾患を含むアトピー性アレルギーを処置するための標的としての喘息関連因子
AU2003292939A1 (en) * 2002-12-24 2004-07-22 The University Of British Columbia Angiogenic compounds and uses thereof
JP2006165843A (ja) * 2004-12-06 2006-06-22 Matsushita Electric Ind Co Ltd 画像処理装置
US20080058300A1 (en) * 2006-04-21 2008-03-06 Mclane Michael Induction of weight loss and the selective inhibition of PTP1B
CA2985271A1 (en) * 2007-09-06 2009-03-12 Ohr Pharmaceutical, Inc. A method for treating diabetes
KR101260221B1 (ko) * 2011-12-01 2013-05-06 주식회사 엘지화학 마스크
KR20150003798A (ko) 2012-04-20 2015-01-09 오에이치알 파마서티컬, 인코포레이티드 Ptp1b 연관 질병의 치료용 아미노스테로이드

Also Published As

Publication number Publication date
PT2838907T (pt) 2019-08-05
US20250002525A1 (en) 2025-01-02
US9546194B2 (en) 2017-01-17
KR20190034685A (ko) 2019-04-02
EP3556765B1 (en) 2022-02-23
HUE044769T2 (hu) 2019-11-28
US20230203088A1 (en) 2023-06-29
EP2838907A2 (en) 2015-02-25
US20200270300A1 (en) 2020-08-27
DK2838907T3 (da) 2019-08-05
KR20150003798A (ko) 2015-01-09
CA2870671C (en) 2020-05-12
AU2013249111A1 (en) 2014-11-06
US10556923B2 (en) 2020-02-11
AU2020203736B2 (en) 2021-12-02
US11434257B2 (en) 2022-09-06
HRP20191348T1 (hr) 2019-10-18
TR201911039T4 (tr) 2019-08-21
JP2019059781A (ja) 2019-04-18
AU2013249111B2 (en) 2018-08-09
PL2838907T3 (pl) 2019-12-31
KR102057812B1 (ko) 2019-12-19
KR20160091435A (ko) 2016-08-02
AU2018256561B2 (en) 2020-03-05
US20150099727A1 (en) 2015-04-09
JP2017178951A (ja) 2017-10-05
JP2015514781A (ja) 2015-05-21
JP2021073250A (ja) 2021-05-13
WO2013158970A3 (en) 2013-12-12
MX2014012619A (es) 2015-01-15
US20190202858A1 (en) 2019-07-04
MX2019009539A (es) 2019-09-26
AU2020203736A1 (en) 2020-06-25
KR101963312B1 (ko) 2019-03-28
EP3556765A1 (en) 2019-10-23
WO2013158970A2 (en) 2013-10-24
EP2838907B1 (en) 2019-05-22
US20170129914A1 (en) 2017-05-11
ES2736310T3 (es) 2019-12-27
CA2870671A1 (en) 2013-10-24
JP6165843B2 (ja) 2017-07-19
AU2018256561A1 (en) 2018-11-22
JP6457010B2 (ja) 2019-01-23
HK1205516A1 (en) 2015-12-18

Similar Documents

Publication Publication Date Title
AU2018256561A1 (en) Aminosteroids for the treatment of a PTP1B associated disease
LTC2785706I2 (lt) Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui
HUS1900007I1 (hu) Kiméra, antigénreceptor-módosított T-sejt alkalmazása rák kezelésére
PT2686347T (pt) Anticorpos dirigidos contra cd70
GEP201706612B (en) Methods for the treatment of breast cancer
ZA201209644B (en) Extending the number of general purpose registers available to instructions
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
IL229495B (en) A sigma receptor ligand for the treatment of pain resulting from type ii diabetes
EA201390948A1 (ru) Лечение боли, обусловленной смещением базального слоя эндометрия
MY167652A (en) Disposable diaper
CO7160080A2 (es) Composiciones lipídicas de racecadotrillo
MX357656B (es) Alfa-1-microglobulina para usarse en tratamiento de enfermedades relacionadas a mitocondrias.
EP3015864A4 (en) Biomarkers for the diagnosis and the response to treatment of pancreatic cancer
GB2509663A (en) Treatment of adrenal insufficiency
IL231498B (en) Compositions for the treatment of peripheral ulcers of various origins
PL2560662T3 (pl) Sulodeksyd do zastosowania w leczeniu patologii, w których uczestniczą metaloproteinazy
GB201114289D0 (en) Flurbiprofen and related compounds for the treatment of skin diseases
ZA201400488B (en) Compounds for the treatment of cancers associated with human papillomavirus
IL234494B (en) Composition for the treatment of menopausal symptoms
PH12014501052A1 (en) Methods and compositions for the treatment of diabetes and related symptoms
FR2987092B1 (fr) Ensemble de reducteurs.
MY184721A (en) Use of odiparcil in the treatment of a mucopolysaccharidosis
GB201009091D0 (en) Compounds for the treatment of clostridium difficile-associated disease
MX2013006526A (es) Dosis de los derivados de arilsulfonamida.
AU332577S (en) A bath (eclipse)

Legal Events

Date Code Title Description
FG Grant or registration